Deep brain stimulation (DBS) surgery is carried out as part of treatment of various neural debilitating conditions such as Parkinson’s disease, dementia, and Alzheimer’s disease. Patients fitted with a deep brain stimulation device can get long-term relief from debilitating symptoms of Parkinson’s disease. There is significant reduction in side-effects caused due to medications, though medications may be required in some patient post-surgery. The DBS device is mainly placed in one of the three FDA approved target sites in Parkinson’s disease. Most commonly preferred target sites are the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN).
Aging increases the risk of Alzheimer’s disease, Parkinson’s disease and dementia. Thus, growing geriatric population is a major factor driving demand for deep brain stimulation devices. Though drug therapies are available for treating these diseases, surgical procedures are recommended in later stages of the condition. Furthermore, deep brain stimulation devices reduce the side effects and improves patient condition by reducing incidence of tremors. Patients are inclined towards adoption of minimally invasive procedures, as these require low healing time and leave behind minimal scars. Surgeons too prefer such procedures as it significantly reduces risk element from accidental damage to surrounding tissue. This is another factor fueling demand for deep brain stimulation devices globally. However, as these devices need to be implanted in the brain, it is extremely challenging and in turn reduces acceptance of DBS devices among patients.
Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/84
Rising incidence rate of Parkinson’s disease is expected to fuel the deep brain stimulation devices market growth
According to the Parkinson’s disease Foundation, as of 2016, over 10 million people are suffering from Parkinson’s disease globally. The findings published by the organization showed that incidence rate of PD increases with age and only 4% of people were diagnosed with PD before the age of 50 years. According to the Parkinson’s disease Foundation, incidence rate of PD in the U.S is as high as 60,000 each year. According to Parkinson’s Australia Inc., around 11,544 new cases of PD were diagnosed in Australia in 2014 and as per the statistics released by Parkinson Canada, the number of people suffering from Parkinson’s disease in Canada is expected to increase to over 163,700 by 2031 (double than the prevalence in 2011). Therefore, increasing incidence of PD across the globe is projected to drive the deep brain stimulation devices market growth.
Aleva Neurotherapeutics SA, Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc., Cyberonics, Inc., and Neuronetics
This report segments the global deep brain stimulation devices market on the basis of application and geography. Applications of deep brain stimulation devices are Parkinson’s disease, essential tremor, dystonia, and others. For comprehensive understanding of market dynamics, the global market has been divided into key geographical regions, namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is further segmented on the basis of major countries for a macro-level understanding of the market.
- Global Deep Brain Stimulation Devices Market, By Application:
- Parkinson’s Disease
- Essential Tremor
- Global Deep Brain Stimulation Devices Market, By Geography:
- North America
- Latin America
- Middle East
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154